A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex

HIV Infections Clinical Trial

Official title:

A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00002163
• Other study ID #: 238B
• Secondary ID: CNAB 3001
• Status: Completed
• Phase: Phase 3
• First received: November 2, 1999
• Last updated: June 23, 2005

Study information

• Verified date: November 1998
• Source: NIH AIDS Clinical Trials Information Service
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

To evaluate the benefit of adding 1592U89 to current antiretroviral therapies for AIDS dementia complex and to assess the safety and tolerance of the treatment regimens.

Description:

Patients must be on stable antiretroviral treatment for at least 6 weeks prior to study entry and will then be stratified depending on whether their regimen contains zidovudine (ZDV). Each stratum will be randomized separately to receive 1592U89 or placebo for 12 weeks. For the subsequent 40 weeks, open-label 1592U89 will be offered.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria

Patients must have:

• Documented HIV infection.

• Evidence of HIV - associated dementia.

• Been on stable antiretroviral treatment for a minimum of 6 weeks prior to study entry.

Exclusion Criteria

Co-existing Condition:

Patients with any of the following symptoms or conditions are excluded:

• Debilitated as a result of their HIV disease, associated illness or therapies who the investigator determines will not be able to complete the 12 week randomized dosing period.

• Memorial Sloan-Kettering (MSK) score of >= 3 for dementia.

• Confounding neurological diseases which may interfere with interpretation of neurological and neurophysical assessments.

• Malabsorption syndrome or other gastrointestinal dysfunction which renders them unable to take oral medication.

• Chronic diseases such as diabetes, congestive heart failure, cardiomyopathy, other cardiac dysfunctions, etc., which in the investigator's opinion would compromise the safety of the patient.

• Symptomatic AIDS-defining opportunistic infection not responsive to therapy.

Concurrent Medication:

Excluded:

• Treatment with cytotoxic chemotherapeutic agents within the first 12 weeks of the study.

• Treatment with nerve growth factor within the first 12 weeks of study.

• The use of narcotic analgesics, sedatives, benzodiazepines, antidepressants, anti-psychotic agents and other psychoactive drugs which would interfere with the assessment of the neurological and neurophysical status of the patient.

• Use of stavudine (d4T) during the first 12 weeks of the study.

• Immunomodulating agents (except GM/G-CSF or epoietin).

• Psychoactive drugs (at the investigator's discretion).

Concurrent Treatment:

Excluded:

• Treatment with radiation therapy within the first 12 weeks of the study.

NOTE:

• With the exception of local treatment for Kaposi's sarcoma.

Patients with any of the following prior conditions are excluded:

• Previous neurological disease unrelated to HIV infection.

• History of clinically apparent hepatitis within the last 6 months.

• History of clinically apparent pancreatitis in the last 6 months.

Prior Medication:

Excluded:

• Treatment with cytotoxic chemotherapeutic agents within 1 month of entry.

• Participation in investigational antiretroviral trials within the past 3 months.

• HIV vaccine within the past 3 months.

• Treatment with immunomodulating agents such as systemic corticosteroids, interleukins, thalidomide, anticytokine agents, anti-oxidants or interferons within 1 month of study entry.

• Nerve growth factor.

Prior Treatment:

Excluded:

• Treatment with radiation therapy within 1 month of entry.

NOTE:

• With the exception of local treatment for Kaposi's sarcoma.

Risk Behavior:

Excluded:

Current alcohol or illicit drug use which may interfere with the patient's ability to comply with the study protocol.

Required:

• Stable antiretroviral treatment that has been ongoing for a minimum of 6 weeks prior to study entry, may or may not include ZDV.

Required:

• Stable antiretroviral treatment for a minimum of 6 weeks prior to study entry.

Study Design

Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• AIDS Dementia Complex
• Dementia
• HIV Infections

Intervention

Drug:
• Abacavir sulfate

Locations

Country	Name	City	State
Canada	Wellesley Hosp	Toronto	Ontario
Canada	Univ of Manitoba / Faculty of Medicine	Winnipeg	Manitoba
United States	Johns Hopkins Univ School of Medicine	Baltimore	Maryland
United States	Univ of North Carolina School of Medicine	Chapel Hill	North Carolina
United States	Columbia Univ / Sergievsky Ctr	New York	New York
United States	Mount Sinai Med Ctr	New York	New York
United States	HIV Neurobehavioral Research Ctr	San Diego	California
United States	San Francisco Gen Hosp	San Francisco	California
United States	Washington Univ Med Ctr	St Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Glaxo Wellcome

Countries where clinical trial is conducted

United States,  Canada, 

References & Publications (1)

Lanier ER, Sturge G, McClernon D, Brown S, Halman M, Sacktor N, McArthur J, Atkinson JH, Clifford D, Price RW, Simpson D, Torres G, Catalan J, Marder K, Power C, Hall C, Romero C, Brew B. HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir. AIDS. 2001 Apr 13;15(6):747-51. — View Citation